Search

Abhinandini Sharma Phones & Addresses

  • 3541 Johnson Ct, Fremont, CA 94555
  • San Jose, CA
  • San Diego, CA

Publications

Us Patents

N-Terminus Conformationally Constrained Glp-1 Receptor Agonist Compounds

View page
US Patent:
20120046222, Feb 23, 2012
Filed:
Mar 26, 2010
Appl. No.:
13/260702
Inventors:
Josue Alfaro-Lopez - San Marcos CA, US
Abhinandini Sharma - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Assignee:
Amylin Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 38/17
A61P 3/10
A61K 38/26
A61P 3/04
C07K 14/605
C07K 14/435
US Classification:
514 53, 530308, 530324, 514 69, 514 72, 514 48, 514 68, 514 67
Abstract:
The disclosure provides N-terminus conformationally constrained compounds, which may comprise peptide mimetics and/or amino acid substitutions, which may be used in peptides, such as GLP-1 receptor agonist compounds, to induce a β-turn secondary structure at the N-terminus. The N-terminus conformationally constrained compounds may be used for research purposes; to produce GLP-1 receptor agonist compounds having improved GLP-1 receptor binding activity, enzymatic stability, or in vivo glucose lowering activity; and to develop GLP-1 receptor agonist compounds which have fewer amino acid residues. The disclosure also provides GLP-1 receptor agonist compounds, such as exendins, exendin analogs, GLP-1 (7-37), GLP-1 (7-37) analogs, comprising the N-terminus conformationally constrained compounds. The compounds are useful for treating various diseases, such as diabetes and obesity. The disclosure also provides methods for chemically synthesizing the N-terminus conformationally constrained compounds.

Glp-1 Receptor Agonist Compounds Having Stabilized Regions

View page
US Patent:
20130184203, Jul 18, 2013
Filed:
Jul 27, 2011
Appl. No.:
13/812445
Inventors:
Josue Alfaro-Lopez - San Diego CA, US
Abhinandini Sharma - San Diego CA, US
Christopher J. Soares - San Diego CA, US
Eugene Coats - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Assignee:
AstraZeneca Pharmaceuticals LP - Wilmington DE
Amylin Pharmaceuticals, LLC - San Diego CA
International Classification:
C07K 14/605
US Classification:
514 53, 530308, 514 117, 514 72, 514 67
Abstract:
The disclosure provides GLP-1 receptor agonist compounds having stabilized regions corresponding to alpha-helical regions of the natural peptide compounds. The disclosure also provides benzamide-containing exendin-4 analogs and alkene-constrained exendin-4 analogs, both of which have stabilized regions corresponding to alpha-helical regions of exendin-4.

Engineered Polypeptides Having Enhanced Duration Of Action With Reduced Immunogenicity

View page
US Patent:
20180344813, Dec 6, 2018
Filed:
Jun 9, 2016
Appl. No.:
15/177397
Inventors:
Mary ERICKSON - San Diego CA, US
David C. LITZINGER - San Diego CA, US
Soumitra S. GHOSH - San Diego CA, US
Zijian GUO - San Diego CA, US
Manoj P. SAMANT - San Diego CA, US
Abhinandini SHARMA - San Diego CA, US
Lala MAMEDOVA - San Diego CA, US
Odile Esther LEVY - San Diego CA, US
Caroline EKBLAD - San Diego CA, US
International Classification:
A61K 38/26
A61K 9/08
A61K 9/19
A61P 3/10
Abstract:
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.

Engineered Polypeptides Having Enhanced Duration Of Action

View page
US Patent:
20170114114, Apr 27, 2017
Filed:
Jan 4, 2017
Appl. No.:
15/398627
Inventors:
- San Diego CA, US
- Wilmington DE, US
Soumitra S. Ghosh - San Diego CA, US
Zijian Guo - San Diego CA, US
Swetha Neravetla - San Diego CA, US
Chengzao Sun - San Marcos CA, US
Manoj P. Samant - Boston MA, US
Odile E. Levy - San Diego CA, US
Abhinandini Sharma - San Diego CA, US
Lala Mamedova - San Diego CA, US
Christopher Soares - La Jolla CA, US
International Classification:
C07K 14/575
Abstract:
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.

Engineered Polypeptides Having Enhanced Duration Of Action With Reduced Immunogenicity

View page
US Patent:
20140235535, Aug 21, 2014
Filed:
Jul 3, 2012
Appl. No.:
14/129815
Inventors:
Mary Erickson - San Diego CA, US
David C. Litzinger - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Zijian Guo - San Diego CA, US
Manoj P. Samant - San Diego CA, US
Abhinandini Sharma - San Diego CA, US
Lala Mamedova - San Diego CA, US
Esther Odile Levy - San Diego CA, US
Caroline Ekblad - San Diego CA, US
International Classification:
C07K 14/605
US Classification:
514 53, 530308, 536 234, 514 72, 514 74, 514 117, 4353201, 435325, 435364, 435367, 435360, 4353651, 435352, 435370, 435357, 435350, 435369, 4352542, 435348, 43525233
Abstract:
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.

Engineered Polypeptides Having Enhanced Duration Of Action

View page
US Patent:
20140107019, Apr 17, 2014
Filed:
Mar 28, 2013
Appl. No.:
13/852899
Inventors:
Amylin Pharmaceuticals, LLC - , US
Astrazeneca Pharmaceuticals LP - , US
Soumitra S. GHOSH - San Diego CA, US
Zijian GUO - San Diego CA, US
Swetha NERAVETLA - San Diego CA, US
Chengzao SUN - San Marcos CA, US
Manoj P. SAMANT - Boston MA, US
Odile E. LEVY - San Diego CA, US
Abhinandini SHARMA - San Diego CA, US
Lala MAMEDOVA - San Diego CA, US
Christopher J. SOARES - La Jolla CA, US
Assignee:
ASTRAZENECA PHARMACEUTICALS LP - Wilmington DE
AMYLIN PHARMACEUTICALS, LLC - San Diego CA
International Classification:
C07K 14/605
US Classification:
514 48, 514 72, 514 164, 514 177, 514 178, 530308
Abstract:
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.
Abhinandini Sharma from Fremont, CA, age ~46 Get Report